undamentalytics Newsletter
Sign in

Crescent Biopharma, Inc. key statistics and ratios

In fiscal 2025, Crescent Biopharma, Inc. had return on equity of -127.5%, an operating margin of -1407.5%, debt equal to 0.0% of equity and a current ratio of 6.56. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162020Dec 20202021Dec 20212022Dec 20222023Dec 20232025Dec 2025
Operating margin23.8%−265.7%−74.1%−63.7%<−999%−506.8%<−999%<−999%<−999%<−999%
Net margin24.0%−265.6%−74.0%−63.6%<−999%−502.1%<−999%<−999%<−999%<−999%
Free-cash-flow margin−70.7%−391.2%−29.9%−42.4%<−999%−386.8%<−999%<−999%<−999%−668.1%
Return on equity29.2%−137.4%−41.4%−28.0%−84.0%−62.4%−60.5%−75.0%−90.7%−127.5%
Return on assets—−200.7%−35.6%−24.2%−70.0%−55.1%−53.5%−63.9%−76.0%−107.8%
Asset turnover—0.760.480.380.000.110.010.000.000.08
Current ratio—2.148.696.106.4011.137.685.716.416.56
Debt to equity0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest cover (operating income ÷ interest)—————————n/m
R&D as % of revenue61.9%293.1%130.2%124.8%>999%442.1%>999%>999%>999%>999%
SG&A as % of revenue14.3%72.6%43.9%———————
Capital spending as % of revenue2.1%2.1%1.4%1.3%>999%0.7%1.3%112.3%213.9%8.5%
Free cash flow ÷ net income−295.1%—————————

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $183m
Short-term assets $179mLonger-term assets $4m
What it owes, and who funded it · $183m
Short-term liabilities $19mLonger-term liabilities $1mShareholders' equity $163m
  • Short-term assets cover short-term liabilities $179m of assets due within a year against $19m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $179m short-term assets against $966,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Crescent Biopharma, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CBIO vs LGVNCBIO vs STTKCBIO vs DARE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crescent Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crescent Biopharma, Inc.